Qiagen N V Quick Ratio (QGEN) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Qiagen N v   (NYSE: QGEN)

Qiagen N V 's Quick Ratio

QGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 5.07 above Qiagen N V average.

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Quick Ratio than Qiagen N V in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 130, from total ranking in the third quarter 2025 at 360.

Explain Quick Ratio?
How much Cash & cash equivalents QGEN´s has?
What are QGEN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

QGEN Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -72.38 % -46.87 % -46.87 % -46.87 % -9.15 %
Y / Y Cash & cash equivalent Change 6.33 % -4.69 % -4.69 % -4.69 % 101.63 %
Quick Ratio MRQ 5.07 15.12 15.12 15.12 1.32
QGEN's Total Ranking # 130 # 360 # # #
Seq. Current Liabilities Change 183.65 % 0 % 0 % -90.26 % 445.68 %
Seq. Cash & cash equivalent Change -4.97 % 0 % 0 % 11.9 % -14.83 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 44
Overall Market # 130


Quick Ratio Statistics
High Average Low
15.12 3.4 0.57
(Dec 31 2025)   (Dec 31 2011)




Financial Statements
Qiagen N V 's Current Liabilities $ 206 Millions Visit QGEN's Balance sheet
Qiagen N V 's Cash & cash equivalent $ 1,044 Millions Visit QGEN's Balance sheet
Source of QGEN's Sales Visit QGEN's Sales by Geography


Cumulative Qiagen N V 's Quick Ratio

QGEN's Quick Ratio for the trailling 12 Months

QGEN Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -63.33 % -21.72 % -41.81 % -52.55 % -59.25 %
Y / Y Cash & cash equivalent TTM Growth -2.25 % 8.43 % 12.52 % 16.81 % 21.33 %
Quick Ratio TTM 10.24 4.44 4.21 4.02 3.84
Total Ranking TTM # 4452 # 3585 # # #
Seq. Current Liabilities TTM Growth -56.02 % -6.23 % -5.87 % -5.54 % -6.1 %
Seq. Cash & cash equivalent TTM Growth 1.45 % -1.25 % -1.23 % -1.22 % 12.54 %

Quick ratio ranking by company, industry and sector >> Back to QGEN Financial Strength Comparisons >> Go to Compare QGEN Quick Ratio to its Competitors

On the trailing twelve months basis QGEN Cash & cash equivalent improved by 6.33 % in Q4 2025 year on year, while Current Liabilities more than doubled to $206 millions, this led to increase in in Qiagen N V 's Quick Ratio to 10.24, above QGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 155 other companies have achieved higher Quick Ratio than Qiagen N V . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3585 to 4452.

Explain Quick Ratio?
How much Cash & cash equivalents QGEN´s has?
What are QGEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 156
Healthcare Sector # 974
Within the Market # 4452


trailing twelve months Quick Ratio Statistics
High Average Low
3.13 1.46 0.7
(Dec 31 2017)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Crispr Therapeutics Ag  13.25 $ 1,975.828  Millions$ 149.120  Millions
Tscan Therapeutics Inc   13.22 $ 152.406  Millions$ 11.528  Millions
Eikon Therapeutics Inc   13.15 $ 335.975  Millions$ 25.549  Millions
Precision Biosciences Inc  12.97 $ 115.585  Millions$ 8.913  Millions
Beam Therapeutics Inc   12.85 $ 1,245.210  Millions$ 96.935  Millions
Anavex Life Sciences Corp   12.60 $ 102.577  Millions$ 8.141  Millions
Vaxcyte Inc   12.49 $ 1,560.959  Millions$ 124.972  Millions
Kalaris Therapeutics Inc   12.15 $ 117.982  Millions$ 9.714  Millions
Imagenebio Inc   12.05 $ 135.349  Millions$ 11.234  Millions
Taysha Gene Therapies Inc   12.04 $ 319.767  Millions$ 26.552  Millions
Immunovant Inc   10.40 $ 713.971  Millions$ 68.677  Millions
Cullinan Therapeutics Inc   10.22 $ 377.896  Millions$ 36.961  Millions
X4 Pharmaceuticals Inc  9.82 $ 252.998  Millions$ 25.757  Millions
Molecular Partners Ag  9.44 $ 104.149  Millions$ 11.027  Millions
4d Molecular Therapeutics Inc   9.15 $ 402.655  Millions$ 43.985  Millions
Prokidney Corp   9.10 $ 270.017  Millions$ 29.671  Millions
Sab Biotherapeutics Inc   9.04 $ 96.592  Millions$ 10.681  Millions
Denali Therapeutics Inc   8.82 $ 867.879  Millions$ 98.351  Millions
Artiva Biotherapeutics Inc   8.25 $ 108.008  Millions$ 13.087  Millions
Black Diamond Therapeutics Inc   8.18 $ 128.652  Millions$ 15.731  Millions
Zura Bio Limited  8.02 $ 109.407  Millions$ 13.647  Millions
Aura Biosciences Inc   7.85 $ 144.241  Millions$ 18.383  Millions
Replimune Group Inc   7.76 $ 483.804  Millions$ 62.362  Millions
Allogene Therapeutics Inc   7.70 $ 250.210  Millions$ 32.514  Millions
Compugen Ltd  7.67 $ 145.640  Millions$ 18.999  Millions
Voyager Therapeutics Inc   7.40 $ 196.447  Millions$ 26.541  Millions
Scholar Rock Holding Corp  7.37 $ 367.563  Millions$ 49.869  Millions
Krystal Biotech Inc   7.27 $ 827.791  Millions$ 113.861  Millions
Metagenomi Therapeutics Inc   7.01 $ 160.799  Millions$ 22.933  Millions

Date modified: 2026-07-07T12:43:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.